Abstract
Flavonoids are present in a wide range of plants. They have been used in the treatment of cancer, but the mechanism underlying this activity is unclear. In recent years, microRNA (miRNA) and long non-coding RNA (lncRNA) levels have been observed to differ between normal tissues and cancer cells, and both types of RNA have been shown to have a role in tumor treatment. In addition, flavonoids have been proven to regulate miRNAs and LncRNAs in the treatment of cancer. The competing endogenous RNA (ceRNA) network is a complex post-transcriptional regulatory mechanism in cells, in which coding and non-coding RNAs competitively bind miRNAs to regulate messenger RNAs (mRNAs). This review focused on the role of the ceRNA network in the treatment of cancer by flavonoids.
Introduction
Flavonoids are a group of polyphenol compounds, including flavones, flavanols, chalcone and others, with a C6-C3-C6 structure (1). They are widely distributed in nature, mainly in plants and fruit. For instance, chrysin is found in the stems and seeds of plants in the family Bignoniaceae and Pinus bungeana. There is growing evidence that a range of flavonoids have strong pharmacological effects, such as anti-inflammatory, vascular protective, anti-oxidative, and anti-viral properties (2, 3). A study performed that dietary flavonoid intake is associated with a reduced risk of different types of cancer, such as gastric, breast, prostate, and colorectal cancers (4). A few studies have also demonstrated an important role of flavonoids in cancer treatment by mechanisms such as inducing apoptosis and inhibiting proliferation. Flavones, such as vitexin can suppress melanoma cell growth (5), chrysin and luteolin can induced apoptosis in HeLa cells (6, 7). Myricetin, as a member of flavonols, can prevent the incidence of colorectal tumorigenesis and reduce the size of colorectal polyps (8). Flavanonol taxifolin can inhibit the migration and invasion of breast cancer cells (9). These evidences suggest that various flavonoids have positive effects on anti-cancer.
The competing endogenous RNA (ceRNA) hypothesis was initially proposed in 2011 (10). It suggested that various RNAs may regulate each other through microRNAs (miRNAs). Previous studies usually focused only on the unidirectional regulation between miRNA and target genes. It was clear that the mechanism of action of miRNAs involved inhibiting mRNA translation or promoting mRNA degradation (11). The ceRNA hypothesis proposed that RNAs can regulate one another by using the same miRNA response elements (MREs) as a molecular sponge to competitively bind miRNAs (12). This advanced our understanding of the function of non-coding RNAs (ncRNAs). A large part of the human transcriptional genome comprises ncRNAs, and they have a reported role in cancer. Compared with normal tissues, numerous ncRNAs show differential expression in cancer tissues (13). Previous studies have proved that abnormally expressed long ncRNAs (lncRNAs) can promote cancer through the ceRNA network, whereas reversing the expression of LncRNAs can inhibit tumor growth (14–16).
In addition, sequencing results have shown that flavonoids, such as galangin, baicalein, chrysin, can change the expression level of mRNAs in tumors, as well as causing the differential expression of miRNAs and LncRNAs (https://www.ncbi.nlm.nih.gov/geo/). These evidences suggest that the anti-cancer mechanism of flavonoids may be related to the regulation of the ceRNA network (Figure 1).
Figure 1
miRNAs and the ceRNA Network
miRNAs are small single-stranded ncRNAs with a length of about 20 nucleotides (nt) (17). After a series of processing steps from the nucleus to the cytoplasm, miRNAs finally mature and assemble with Argonaute (Ago) family proteins to form the RNA-induced silencing complex (RISC) (18, 19). The parts of the target transcript that complement the miRNA sequences are called MREs; they are specifically recognized by miRNAs and guide the RISC to target RNAs, thereby either inhibiting the translation or inducing the degradation of the target mRNA. In humans, the base pairing between miRNAs and their targets is not usually highly specific, which makes the regulatory ability of miRNAs more extensive (20). With the progress of sequencing technology, numerous miRNAs have been characterized and differential changes have been found in various cancers (21). In this context, microRNAs are usually divided into two categories: carcinogenic miRNAs, which are generally highly expressed in tumors, inhibit tumor-suppressor genes, and promote the occurrence and development of tumors, such as miR-675 (22) and miR-501-5p (23); and tumor-suppressor miRNAs, such as miR-199a-3p (24) and miR-101 (25). Notably, the role of miRNAs has tissue specificity. For example, miR-125b can inhibit cell proliferation and induce apoptosis in colon cancer, and participate in tumor drug-resistance in hepatocellular carcinoma (HCC) (26, 27). miRNAs are central to the ceRNA network, through which RNAs can regulate others with similar MRE communication. In addition, a recent study found that the flavonoid scutellarin could alter the miRNA-expression profile of hepatoma cells (28). These findings suggest that regulating miRNA expression is an important mechanism-of-action of flavonoids in cancer treatment.
LncRNAs as Molecular Sponges in the ceRNA Regulatory Network
LncRNAs are ncRNAs with a length of more than 200 bases, which are transcribed by RNA polymerase II. Although LncRNAs do not encode proteins, they have a variety of biological functions, including gene activation and silencing, alternative splicing, and post-translational modification (29, 30).
On the one hand, LncRNAs can form miRNA precursors through intracellular shear and further progress into mature miRNAs. On the other hand, as an important part of the ceRNA network, LncRNAs are rich in MREs, which allows them to act as a molecular sponge to competitively bind miRNAs and regulate their targets.
A large number of differentially expressed LncRNAs have been found in cancer. Similar to miRNAs, LncRNAs can be divided into cancer-promoting and cancer-inhibiting types. The most common oncogenic LncRNA-H19 was one of the first to be described (31), and has been proved to be overexpressed in many cancers. H19 overexpression in bladder cancer cells reduces E-cadherin, thereby promoting cell migration and invasion (32), and promotes the epithelial-to-mesenchymal transition in colorectal cancer by absorbing miR-138 and miR-200a (33). In addition, LncRNAs such as LncRNA00364, TPTEP1, and TSLNC8 can inhibit the proliferation and progression of HCC cells (34). Evidence suggests that the abnormal expression of LncRNAs in cancer can be reversed by flavonoids, and has an inhibitory effect on cancer (35). This indicates that flavonoids can regulate the expression of LncRNAs for cancer treatment.
mRNAs are Both Regulators and Regulated in the ceRNA Network
Because mRNAs are eventually translated into proteins that play biological roles, they often appear to be the main targets of regulation in the ceRNA network; however, they can also participate in the post-transcriptional regulation of other genes, which complicates the crosstalk (36). mRNAs can regulate key genes in carcinogenesis and development in an miRNA-dependent manner. HMGA2 can increase the expression of TGFBR3 as a molecular sponge of the let-7a family to promote the occurrence of lung cancer (37). A previous study predicted that NCALD may affect drug resistance and prognosis in ovarian cancer by acting as a ceRNA of CX3CL1 for tumor suppression (38). A large number of reports have shown that flavonoids can regulate mRNAs in tumors to inhibit their progression, and some mRNAs have been proven to be regulated by miRNAs that are affected by flavonoids (39, 40). In conclusion, mRNAs play a prominent role in the anti-cancer effect of flavonoids, and flavonoids can inhibit cancer by regulating mRNAs directly and indirectly.
Flavonoids Can Inhibit Cancer Through the ceRNAsNetwork
Numerous studies have shown that flavonoids play a positive role in the treatment of cancer (41, 42). There are evidences that flavonoids can inhibit various kinds of cancer in many different ways (43–45). Flavonoids can affect both coding RNAs and ncRNAs in cancer cells, suggesting that the regulation of the ceRNA network is involved in the inhibitory effect of flavonoids on the occurrence and development of cancer. Our previous study suggested that chrysin could promote the apoptosis of gastric cancer cells through the H19/miR-Let-7a/COPB2 axis (16). Furthermore, as a kind of flavonols, quercetin can inhibit proliferation and invasion by up-regulating miR-146a in human breast cancer cells (46), and increase the sensitivity of non-small-cell lung cancer cells to radiotherapy by regulating the miR-16-5p/WEE1 axis (47). Aside from inhibiting cancer, flavonoids can reverse drug resistance through the ceRNA network.
We further analyzed the sequencing data of gastric cancer cells treated with chrysin (Gene Expression Omnibus [GEO] accession: GSE181492). The results showed that chrysin could regulate the mRNA expression of nuclear factor kappa B (NFκB), p53, and other signaling pathways, which may be a key link in the complex anticancer effect of chrysin (Figure 2). Moreover, we found that some LncRNAs, miRNAs, and mRNAs were expressed abnormally in stomach adenocarcinoma (STAD), but the reverse pattern was seen in gastric cancer cells treated with chrysin. Notably, only miR-6739 was found to have a rescue effect on chrysin in the sequencing results. It was upregulated in gastric cancer and downregulated after chrysin treatment. This indicated that miRNA may play key roles in the chrysin treatment of gastric cancer. According to the prediction of its direct target gene by MREs, chrysin may inhibit gastric cancer via miR-6739 through peroxisome proliferator-activated receptor (PPAR) and other pathways.
Figure 2
Discussion
Existing cancer treatment mainly involves surgical resection supplemented by chemotherapy. Apart from having side-effects for patients, chemotherapy also has an important limitation in terms of drug resistance. However, some of the members of flavonoids can reverse drug resistance of cancers by various ways. For example, baicalein can increase cisplatin sensitivity of A549 lung adenocarcinoma cells (48). Luteolin can enhance chemosensitivity of breast cancer through the Nrf2-Mediated pathway (49). Quercetin can increase the chemosensitivity of breast cancer to doxorubicin Via PTEN/Akt pathway (50). Therefore, flavonoids might can be used to reduce the side-effects of chemotherapy drugs and increase the sensitivity of tumors. Studies have shown that abnormal miRNA and LncRNA expression can cause drug resistance in cancer (51, 52). The flavonoids mentioned above may reverse drug resistance with the help of the ceRNA network; flavonoids may therefore be used to reduce the side-effects of chemotherapy drugs and increase the sensitivity of tumors, in order to treat cancer more safely and effectively. In addition, there is evidence that quercetin, chrysin, luteolin and other flavonoids contribute to wound healing (53), which may aid patients’ postoperative recovery. These make flavonoid drugs have a better prospect in the combination of other drugs in the treatment of cancer.
In conclusion, the ceRNA network plays an important role in cancer treatment with flavonoids. Flavonoids can regulate cancer-related genes via the ceRNA network. Moreover, the ceRNA network can have additional effects that may help patients with treatment and recovery. These findings show that the ceRNA network offers new prospects for the use of flavonoids in anti-cancer treatment.
Funding
This work was supported by Natural science Foundation of the Jilin province (20210101310JC) and Chinese Postdoctoral International Exchange Program.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
CL and DW wrote the manuscript. CL, XL, ZJ, LS, YH, and JL collected the references and prepared figures. All authors reviewed the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
PeiRLiuXBollingB. Flavonoids and Gut Health. Curr Opin Biotechnol (2020) 61:153–9. doi: 10.1016/j.copbio.2019.12.018
2
MalekiSJCrespoJFCabanillasB. Anti-Inflammatory Effects of Flavonoids. Food Chem (2019) 299:125124. doi:Â 10.1016/j.foodchem.2019.125124
3
CiumărneanLMilaciuMVRuncanOVesaȘCRăchișanALNegreanVet al. The Effects of Flavonoids in Cardiovascular Diseases. Molecules (2020) 25(18):4320. doi: 10.3390/molecules25184320
4
RodrÃguez-GarcÃaCSánchez-QuesadaCGaforioJJ. Dietary Flavonoids as Cancer Chemopreventive Agents: An Updated Review of Human Studies. Antioxidants (Basel) (2019) 8(5):137. doi: 10.3390/antiox8050137
5
LiuNWangKSQiMZhouYJZengGYTaoJet al. Vitexin Compound 1, a Novel Extraction From a Chinese Herb, Suppresses Melanoma Cell Growth Through DNA Damage by Increasing Ros Levels. J Exp Clin Cancer Res (2018) 37(1):269. doi:Â 10.1186/s13046-018-0897-x
6
RainaRAfrozeNKedhari SundaramMHaqueSBajboujKHamadMet al. Chrysin Inhibits Propagation of Hela Cells by Attenuating Cell Survival and Inducing Apoptotic Pathways. Eur Rev Med Pharmacol Sci (2021) 25(5):2206–20. doi: 10.26355/eurrev_202103_25253
7
RainaRPramodhSRaisNHaqueSShafarinJBajboujKet al. Luteolin Inhibits Proliferation, Triggers Apoptosis and Modulates Akt/Mtor and Map Kinase Pathways in Hela Cells. Oncol Lett (2021) 21(3):192. doi:Â 10.3892/ol.2021.12452
8
ZhangMJSuHYanJYLiNSongZYWangHJet al. Chemopreventive Effect of Myricetin, a Natural Occurring Compound, on Colonic Chronic Inflammation and Inflammation-Driven Tumorigenesis in Mice. BioMed Pharmacother (2018) 97:1131–7. doi: 10.1016/j.biopha.2017.11.018
9
LiJHuLZhouTGongXJiangRLiHet al. Taxifolin Inhibits Breast Cancer Cells Proliferation, Migration and Invasion by Promoting Mesenchymal to Epithelial Transition Via B-Catenin Signaling. Life Sci (2019) 232:116617. doi:Â 10.1016/j.lfs.2019.116617
10
SalmenaLPolisenoLTayYKatsLPandolfiPP. A Cerna Hypothesis: The Rosetta Stone of a Hidden Rna Language? Cell (2011) 146(3):353–8. doi: 10.1016/j.cell.2011.07.014
11
CaiYYuXHuSYuJ. A Brief Review on the Mechanisms of Mirna Regulation. Genomics Proteomics Bioinf (2009) 7(4):147–54. doi: 10.1016/s1672-0229(08)60044-3
12
KarrethFAPandolfiPP. Cerna Cross-Talk in Cancer: When Ce-Bling Rivalries Go Awry. Cancer Discov (2013) 3(10):1113–21. doi: 10.1158/2159-8290.Cd-13-0202
13
SlackFJChinnaiyanAM. The Role of Non-Coding Rnas in Oncology. Cell (2019) 179(5):1033–55. doi: 10.1016/j.cell.2019.10.017
14
LiHWangXWenCHuoZWangWZhanQet al. Long Noncoding Rna Norad, a Novel Competing Endogenous Rna, Enhances the Hypoxia-Induced Epithelial-Mesenchymal Transition to Promote Metastasis in Pancreatic Cancer. Mol Cancer (2017) 16(1):169. doi:Â 10.1186/s12943-017-0738-0
15
KongXDuanYSangYLiYZhangHLiangYet al. Lncrna-Cdc6 Promotes Breast Cancer Progression and Function as Cerna to Target Cdc6 by Sponging Microrna-215. J Cell Physiol (2019) 234(6):9105–17. doi: 10.1002/jcp.27587
16
ChenLLiQJiangZLiCHuHWangTet al. Chrysin Induced Cell Apoptosis Through H19/Let-7a/Copb2 Axis in Gastric Cancer Cells and Inhibited Tumor Growth. Front Oncol (2021) 11:651644. doi:Â 10.3389/fonc.2021.651644
17
Lagos-QuintanaMRauhutRLendeckelWTuschlT. Identification of Novel Genes Coding for Small Expressed Rnas. Science (2001) 294(5543):853–8. doi: 10.1126/science.1064921
18
LeeYJeonKLeeJTKimSKimVN. Microrna Maturation: Stepwise Processing and Subcellular Localization. EMBO J (2002) 21(17):4663–70. doi: 10.1093/emboj/cdf476
19
KobayashiHTomariY. Risc Assembly: Coordination Between Small Rnas and Argonaute Proteins. Biochim Biophys Acta (2016) 1859(1):71–81. doi: 10.1016/j.bbagrm.2015.08.007
20
ZealyRWWrennSPDavilaSMinKWYoonJH. Microrna-Binding Proteins: Specificity and Function. Wiley Interdiscip Rev RNA (2017) 8(5):10. doi:Â 10.1002/wrna.1414
21
VishnoiARaniS. Mirna Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol (2017) 1509:1–10. doi: 10.1007/978-1-4939-6524-3_1
22
GuanGFZhangDJWenLJXinDLiuYYuDJet al. Overexpression of Lncrna H19/Mir-675 Promotes Tumorigenesis in Head and Neck Squamous Cell Carcinoma. Int J Med Sci (2016) 13(12):914–22. doi: 10.7150/ijms.16571
23
FanDRenBYangXLiuJZhangZ. Upregulation of Mir-501-5p Activates the Wnt/B-Catenin Signaling Pathway and Enhances Stem Cell-Like Phenotype in Gastric Cancer. J Exp Clin Cancer Res (2016) 35(1):177. doi:Â 10.1186/s13046-016-0432-x
24
RenKLiTZhangWRenJLiZWuG. Mir-199a-3p Inhibits Cell Proliferation and Induces Apoptosis by Targeting Yap1, Suppressing Jagged1-Notch Signaling in Human Hepatocellular Carcinoma. J BioMed Sci (2016) 23(1):79. doi:Â 10.1186/s12929-016-0295-7
25
YangJLuYLinYYZhengZYFangJHHeSet al. Vascular Mimicry Formation Is Promoted by Paracrine Tgf-B and Sdf1 of Cancer-Associated Fibroblasts and Inhibited by Mir-101 in Hepatocellular Carcinoma. Cancer Lett (2016) 383(1):18–27. doi: 10.1016/j.canlet.2016.09.012
26
ZhangJYangWXiaoYShanL. Mir-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer Sw480 Cells Via Targeting Stat3. Recent Pat Anticancer Drug Discov (2021) 16. doi:Â 10.2174/1574892816666210708165037
27
HiraoASatoYTanakaHNishidaKTomonariTHirataMet al. Mir-125b-5p Is Involved in Sorafenib Resistance Through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Cancers (Basel) (2021) 13(19):4917. doi:Â 10.3390/cancers13194917
28
BieBSunJLiJGuoYJiangWHuangCet al. Baicalein, a Natural Anti-Cancer Compound, Alters Microrna Expression Profiles in Bel-7402 Human Hepatocellular Carcinoma Cells. Cell Physiol Biochem (2017) 41(4):1519–31. doi: 10.1159/000470815
29
EngreitzJMHainesJEPerezEMMunsonGChenJKaneMet al. Local Regulation of Gene Expression by Lncrna Promoters, Transcription and Splicing. Nature (2016) 539(7629):452–5. doi: 10.1038/nature20149
30
LeeSKoppFChangTCSataluriAChenBSivakumarSet al. Noncoding Rna Norad Regulates Genomic Stability by Sequestering Pumilio Proteins. Cell (2016) 164(1-2):69–80. doi: 10.1016/j.cell.2015.12.017
31
BrannanCIDeesECIngramRSTilghmanSM. The Product of the H19 Gene May Function as an Rna. Mol Cell Biol (1990) 10(1):28–36. doi: 10.1128/mcb.10.1.28-36.1990
32
ZhuZXuLWanYZhouJFuDChaoHet al. Inhibition of E-Cadherin Expression by Lnc-Rna H19 to Facilitate Bladder Cancer Metastasis. Cancer biomark (2018) 22(2):275–81. doi: 10.3233/cbm-170998
33
LiangWCFuWMWongCWWangYWangWMHuGXet al. The Lncrna H19 Promotes Epithelial to Mesenchymal Transition by Functioning as Mirna Sponges in Colorectal Cancer. Oncotarget (2015) 6(26):22513–25. doi: 10.18632/oncotarget.4154
34
MohanCDRangappaSNayakSCSethiGRangappaKS. Paradoxical Functions of Long Noncoding Rnas in Modulating Stat3 Signaling Pathway in Hepatocellular Carcinoma. Biochim Biophys Acta Rev Cancer (2021) 1876(1):188574. doi:Â 10.1016/j.bbcan.2021.188574
35
LuXChenDYangFXingN. Quercetin Inhibits Epithelial-To-Mesenchymal Transition (Emt) Process and Promotes Apoptosis in Prostate Cancer Via Downregulating Lncrna Malat1. Cancer Manag Res (2020) 12:1741–50. doi: 10.2147/cmar.S241093
36
SmillieCLSireyTPontingCP. Complexities of Post-Transcriptional Regulation and the Modeling of Cerna Crosstalk. Crit Rev Biochem Mol Biol (2018) 53(3):231–45. doi: 10.1080/10409238.2018.1447542
37
KumarMSArmenteros-MonterrosoEEastPChakravortyPMatthewsNWinslowMMet al. Hmga2 Functions as a Competing Endogenous Rna to Promote Lung Cancer Progression. Nature (2014) 505(7482):212–7. doi: 10.1038/nature12785
38
DongCYinFZhuDCaiXChenCLiuX. Ncald Affects Drug Resistance and Prognosis by Acting as a Cerna of Cx3cl1 in Ovarian Cancer. J Cell Biochem (2020) 121(11):4470–83. doi: 10.1002/jcb.29670
39
ZhongXLiuDJiangZLiCChenLXiaYet al. Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of Tet1 Expression in Gastric Cancer Cells. Onco Targets Ther (2020) 13:3277–87. doi: 10.2147/ott.S246031
40
BhatFASharmilaGBalakrishnanSArunkumarRElumalaiPSuganyaSet al. Quercetin Reverses Egf-Induced Epithelial to Mesenchymal Transition and Invasiveness in Prostate Cancer (Pc-3) Cell Line Via Egfr/Pi3k/Akt Pathway. J Nutr Biochem (2014) 25(11):1132–9. doi: 10.1016/j.jnutbio.2014.06.008
41
LimWRyuSBazerFWKimSMSongG. Chrysin Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction. J Cell Physiol (2018) 233(4):3129–40. doi: 10.1002/jcp.26150
42
KaushikSShyamHAgarwalSSharmaRNagTCDwivediAKet al. Genistein Potentiates Centchroman Induced Antineoplasticity in Breast Cancer Via Pi3k/Akt Deactivation and Ros Dependent Induction of Apoptosis. Life Sci (2019) 239:117073. doi:Â 10.1016/j.lfs.2019.117073
43
LiKZhengQChenXWangYWangDWangJ. Isobavachalcone Induces Ros-Mediated Apoptosis Via Targeting Thioredoxin Reductase 1 in Human Prostate Cancer Pc-3 Cells. Oxid Med Cell Longev (2018) 2018:1915828. doi:Â 10.1155/2018/1915828
44
ShiJChenYChenWTangCZhangHChenYet al. Isobavachalcone Sensitizes Cells to E2-Induced Paclitaxel Resistance by Down-Regulating Cd44 Expression in Er+ Breast Cancer Cells. J Cell Mol Med (2018) 22(11):5220–30. doi: 10.1111/jcmm.13719
45
LeeDEJangEHBangCKimGLYoonSYLeeDHet al. Bakuchiol, Main Component of Root Bark of Ulmus Davidiana Var. Japonica, Inhibits Tgf-B-Induced in Vitro Emt and In Vivo Metastasis. Arch Biochem Biophys (2021) 709:108969. doi:Â 10.1016/j.abb.2021.108969
46
TaoSFHeHFChenQ. Quercetin Inhibits Proliferation and Invasion Acts by Up-Regulating Mir-146a in Human Breast Cancer Cells. Mol Cell Biochem (2015) 402(1-2):93–100. doi: 10.1007/s11010-014-2317-7
47
WangQChenYLuHWangHFengHXuJet al. Quercetin Radiosensitizes Non-Small Cell Lung Cancer Cells Through the Regulation of Mir-16-5p/Wee1 Axis. IUBMB Life (2020) 72(5):1012–22. doi: 10.1002/iub.2242
48
YuMQiBXiaoxiangWXuJLiuX. Baicalein Increases Cisplatin Sensitivity of A549 Lung Adenocarcinoma Cells Via Pi3k/Akt/Nf-Kb Pathway. BioMed Pharmacother (2017) 90:677–85. doi: 10.1016/j.biopha.2017.04.001
49
TsaiKJTsaiHYTsaiCCChenTYHsiehTHChenCLet al. Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity Through the Nrf2-Mediated Pathway. Molecules (2021) 26(21):6452. doi:Â 10.3390/molecules26216452
50
LiSZQiaoSFZhangJHLiK. Quercetin Increase the Chemosensitivity of Breast Cancer Cells to Doxorubicin Via Pten/Akt Pathway. Anticancer Agents Med Chem (2015) 15(9):1185–9. doi: 10.2174/1871520615999150121121708
51
LiMPHuYDHuXLZhangYJYangYLJiangCet al. Mirnas and Mirna Polymorphisms Modify Drug Response. Int J Environ Res Public Health (2016) 13(11):1096. doi:Â 10.3390/ijerph13111096
52
XiaMZuXChenZWenGZhongJ. Noncoding RNAs in Triple Negative Breast Cancer: Mechanisms for Chemoresistance. Cancer Lett (2021) 523:100–10. doi: 10.1016/j.canlet.2021.09.038
53
CarvalhoMTBAraújo-FilhoHGBarretoASQuintans-JúniorLJQuintansJSSBarretoRSS. Wound Healing Properties of Flavonoids: A Systematic Review Highlighting the Mechanisms of Action. Phytomedicine (2021) 90:153636. doi: 10.1016/j.phymed.2021.153636
Summary
Keywords
flavonoids, gastric cancer, miRNA, lncRNA, the competing endogenous RNA network
Citation
Li C, Li X, Jiang Z, Wang D, Sun L, Li J and Han Y (2022) Flavonoids Inhibit Cancer by Regulating the Competing Endogenous RNA Network. Front. Oncol. 12:842790. doi: 10.3389/fonc.2022.842790
Received
24 December 2021
Accepted
22 February 2022
Published
18 March 2022
Volume
12 - 2022
Edited by
Xi-Zhong Shen, Fudan University, China
Reviewed by
Mauricio Rodriguez-Dorantes, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico
Updates
Copyright
© 2022 Li, Li, Jiang, Wang, Sun, Li and Han.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yang Han, hanyang8584@jlu.edu.cn
†These authors have contributed equally to this work and share first authorship
This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.